Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand (RANKL) in the Serum of Healthy Adults

<jats:sec><jats:title>Aims</jats:title><jats:p> Osteoprotegerin and the receptor activator of the nuclear factor-κB ligand (RANKL) are decisive factors for maintaining the balance between bone formation and bone resorption. As new, sensitive ELISAs have been developed recently, reference serum ranges should be established to use these analytes for possible diagnostic purposes. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> Measurements were performed in serum samples of 142 healthy adults (82 women, 60 men) between 20 and 70 years of age (mean age: 46 years) using ELISA kits from Immundiagnostik, Bensheim, Germany. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Serum concentrations of osteoprotegerin were age and gender independent and showed a Gaussian distribution, while RANKL concentrations were also age independent but differed between males and females, with a non-Gaussian distribution. For osteoprotegerin a gender-independent upper 97.5 percentile limit of 3.6 pmol/L was calculated while the corresponding limits for RANKL and the ratio of RANKL to osteoprotegerin amounted to 3.29 pmol/L and 2.78 in women and 1.66 pmol/L and 2.18 in men, respectively. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Both osteoprotegerin and RANKL were quantifiable in serum of healthy adults, which means that these compounds can be used as potential diagnostic tools. </jats:p></jats:sec>